Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jq1234si who wrote (2939)	11/4/2013 1:32:00 PM
From: GregorioAllegri	Read Replies (1) \| Respond to of 4474

OK. Read it. Lots of data in the Medical section. Bottom line (for me) is about 3% died as of July 2012 with cardio [8/444]- or cerebro- [5/444] vascular AEs that MIGHT be attributable to the drug versus hundreds alive because of the drug and with no alternative treatments. I suspect this bottom line has not changed except that we can be rather confident there is a cardio effect of the drug that is not solely a function of being old and sick with CML with a bad ticker or diabetes. On the other hand, with over half the patients STILL on this drug of last resort 3 years plus after the trial has begun is a tribute to both its efficacy and safety [however flawed.] Surprised that time on ponatinib was not used as a variable in their multivariant analysis as that is a measure of the drug causing the effect in part (minus the natural age adjusted death rate.) Perhaps 11 mos. median duration on therapy was not long enough to include this. If they include this they should also include interaction variables (e.g. age*duration on therapy) as healthier, younger people might make up a larger percentage of the AEs as the toxic effects of the drug build up. Multiple regression is a great little hypothesis tester... Three factors in the multivariant analysis that contributed significantly to arterial ischemic (AI) events (mostly non-fatal): Perentages are percent of patients with an Arterial Ischemic event: Age: <50 = 2.1%; 50-65 = 14.9%; 66-74 = 12.4%; >74 = 28.9% Age: <50 = 3/145; 50-65 = 24/161; 66-74 = 13/105; >74 = 11/38 Prior arterial ischemia or any vascular procedure: 35.6% [21/59] (vs. 7.7% [30/390] for those without prior events) Diabetes: 32.1% (vs. 8.4% for those without diabetes) The IC50 table had somewhat different numbers than I have seen elsewhere. Inhibiting FGFR2 at < 1 nMol might have similar effects to VEGFR2 (it also is involved in wound healing and angiogenesis.) Nice little section on the phase one test too shows >20% AI AEs as of July 2012. It does not appear that cardiovascular health was routinely measured except for blood pressure. When the AE came it was noted by the physician and reported as an AE. ga